Epstein-Barr Viral Load is Associated to Response in AIDS-Related Lymphomas

Imagem de Miniatura
Arquivos
art_TANAKA_EpsteinBarr_Viral_Load_is_Associated_to_Response_in_2014.PDF (184.48 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER INDIA
Autores
OHSHIMA, Kouichi
MATSUOKA, Masao
CALORE, Edenilson Eduardo
PEREZ, Nilda Maria
Citação
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, v.30, n.3, p.191-194, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
AIDS-related lymphoma (ARL) development is associated to immunodeficiency state with proliferation of B-cells driven by HIV itself and EBV infection. However, Epstein-Barr DNA is not detected in malignant cells of all ARL subtypes. A prospective and controlled study to analyze EBV viral load (VL) in plasma and peripheral blood mononuclear cells (PBMC) of ARL patients was performed to analyze if Epstein-Barr VL could be related to response in these patients. Fifteen patients with ARL were included in this study with measurement of EBV VL at three different periods of time: at lymphoma diagnosis, upon completion of chemotherapy, and 3 months after. Two control groups composed by HIV-negative and HIV-positive patients were also evaluated for EBV VL comparison. In situ hybridization for EBER was performed on diagnostic samples of all ARL patients. Median EBV VL in PBMC and plasma had a significant decrease (p = 0.022 and p = 0.003, respectively) after ARL treatment. EBER was positive in 7 (46.7 %) cases. Median EBV VL in PBMC before lymphoma treatment in patients positive for EBER was significantly higher compared to EBER negative cases (p = 0.041). Reduction of EBV viral load during treatment of lymphoma could be predictive of response. EBER expression was associated to advanced stages of disease and worse immune status. Our study suggests that measurement of EBV VL during ARL treatment could be used as a marker for response, but further studies are needed to validate this association.
Palavras-chave
Aids-related lymphoma, HIV, EBV
URI
https://observatorio.fm.usp.br/handle/OPI/8463
Referências
  1. Bibas M, 2009, MEDITERR J HEMATOL I, V1
  2. Bonnet F, 2006, J CLIN VIROL, V36, P258, DOI 10.1016/j.jcv.2006.04.005
  3. Cheson BD, 1999, J CLIN ONCOL, V17, P1244
  4. Fan HX, 2005, J MED VIROL, V75, P59, DOI 10.1002/jmv.20238
  5. Goedert JJ, 2000, SEMIN ONCOL, V27, P390
  6. Morales D, 2010, LEUKEMIA LYMPHOMA, V51, P66, DOI 10.3109/10428190903308015
  7. O'Sullivan CE, 2002, J MED VIROL, V67, P320, DOI 10.1002/jmv.10080
  8. Tanaka PY, 2010, ANN HEMATOL, V89, P45, DOI 10.1007/s00277-009-0761-3
  9. Uner A, 2011, APMIS, V119, P309, DOI 10.1111/j.1600-0463.2011.02736.x
  10. van Baarle D, 2002, J INFECT DIS, V186, P405, DOI 10.1086/341460
  11. van Baarle D, 2001, BLOOD, V98, P146, DOI 10.1182/blood.V98.1.146
  12. Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - LIM/46
Carregar mais